Selected original psychedelic research published by Fluence Lead Trainers.
By Elizabeth Nielson, PhD
Gorman, I., Nielson, E.M., Molinar, A., Cassidy, K., & Sabbagh, J. (2021)
Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice.
Front. Psychol. 12:645246. doi: 10.3389/fpsyg.2021.645246
Tai, S. J.,Nielson, E. M., Lennard-Jones, M., Johanna Ajantaival, R. L., Winzer, R.,Richards, W. A., … & Malievskaia, E. (2021).
Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research.
Frontiers in Psychiatry, 12, 27.
Nielson, E. M., & Guss, J. (2018).
The influence of therapists’ first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training.
Journal of Psychedelic Studies, 2(2), 64-73.
Nielson, E. M., May, D. G., Forcehimes, A. A.,& Bogenschutz, M. P. (2018).
The psychedelic debriefing in alcohol dependence treatment: Illustrating key change phenomena through qualitative content analysis of clinical sessions.
Frontiers in Pharmacology, 9, 132.
Nielson, E. M., May, D. G., Forcehimes, A. A.,& Bogenschutz, M. P. (2018).
The psychedelic debriefing in alcohol dependence treatment: Illustrating key change phenomena through qualitative content analysis of clinical sessions.
Frontiers in Pharmacology, 9, 132.
Nielson, E. M.
Psychedelics as a Training Experience for Psychedelic Therapists: Drawing on History to Inform Current Practice.
Journal of Humanistic Psychology. June 2021. doi:10.1177/00221678211021204
Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., . . . Malievskaia, E. (2022).
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
New England Journal of Medicine, 387(18), 1637-1648.
Agin-Liebes, G., Nielson, E. M., Zingman, M., Kim, K., Haas, A., Owens, L. T., Rogers, U., & Bogenschutz, M. (2023, June 5).
Reports of Self-Compassion and Affect Regulation in Psilocybin-Assisted Therapy for Alcohol Use Disorder: An Interpretive Phenomenological Analysis.
Psychology of Addictive Behaviors. Advance online publication. https://dx.doi.org/10.1037/adb0000935
McGuire AL, Cohen IG, Sisti D, et al.
Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement.
JAMA Netw Open. 2024;7(6):e2414650. doi:10.1001/jamanetworkopen.2024.14650
By Ingmar Gorman, PhD
Páleníček, T., Fujáková, M., Brunovský, M.,Balíková, M., Horáček, J., Gorman, I., … & Krajča, V. (2011).
Electroencephalographic spectral and coherence analysis of ketamine in rats: correlation with behavioral effects and pharmacokinetics.
Neuropsychobiology, 63(4), 202-218.
Páleníček, T., Fujáková, M., Brunovský, M.,Horáček, J., Gorman, I., Balíková, M., … & Höschl, C. (2013).
Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats.
Psychopharmacology, 225(1), 75-93.
Fujáková, M., Páleníček, T., Brunovský, M.,Gorman, I., Tylš, F., Kubešová, A., … & Horáček, J. (2014).
The effect of((−)-2-oxa-4-aminobicyclo [3.1. 0] hexane-2, 6-dicarboxylic acid (LY379268), anmGlu2/3 receptor agonist, on EEG power spectra and coherence in ketamine model of psychosis.
Pharmacology Biochemistry and Behavior, 122, 212-221.
Gorman, I., (2015) Drug-assisted Psychotherapy. In Ingersoll, R. E., & Rak, C. F. (2015).
Psychopharmacology for Mental Health Professionals: An Integrative Approach.
Nelson Education.
Winkler, P., Gorman, I., & Kočárová, R.(2016).
Use of LSD by Mental Health Professionals. In Neuropathology of drug addictions and substance misuse (pp. 773-781).
Academic Press.
Gorman, I., Belser, A. B., Jerome, L., Hennigan, C., Shechet, B., Hamilton, S., … & Feduccia, A. A. (2020).
Posttraumatic growth after MDMA‐assisted psychotherapy for posttraumatic stress disorder.
Journal of Traumatic Stress, 33(2), 161-170.
Gorman, I., Nielson, E.M., Molinar, A., Cassidy, K., & Sabbagh, J. (2021)
Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice.
Front. Psychol. 12:645246. doi: 10.3389/fpsyg.2021.645246
By Jeffrey Guss, MD
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone,T., Cohen, B., … & Schmidt, B. L. (2016).
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.
Journal of Psychopharmacology, 30(12), 1165-1180.
Swift, T. C., Belser, A. B., Agin-Liebes, G., Devenot, N.,Terrana, S., Friedman, H. L., … & Ross, S. (2017).
Cancer at the dinner table: experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress.
Journal of Humanistic Psychology, 57(5), 488-519.
Nielson, E. M., & Guss, J. (2018).
The influence of therapists’ first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training.
Journal of Psychedelic Studies,2(2), 64-73.
Malone, T. C., Mennenga, S. E., Guss, J., Podrebarac, S.K., Owens, L. T., Bossis, A. P., … & Ross, S. (2018).
Individual experiences in four cancer patients following psilocybin-assisted psychotherapy.
Frontiers in Pharmacology, 9, 256.
Sloshower, J., Guss, J., Krause, R., Wallace, R. M.,Williams, M. T., Reed, S., & Skinta, M. D. (2020).
Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame.
Journal of Contextual Behavioral Science, 15, 12-19.
Agin-Liebes, G. I., Malone, T.,Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., … & Ross, S.(2020).
Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer.
Journal of Psychopharmacology, 34(2), 155-166.
By Kelan Thomas, PharmD
Nguyen, L., Thomas, K. L., Lucke-Wold, B. P., Cavendish, J.Z., Crowe, M. S., & Matsumoto, R. R. (2016).
Dextromethorphan: An update onits utility for neurological and neuropsychiatric disorders.
Pharmacology & Therapeutics, 159, 1-22.
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C.,Abbas, A. I., Hufeisen, S. J., … & Roth, B. L. (2009).
Predicting new molecular targets for known drugs.
Nature, 462(7270), 175-181.
Thomas, K., Malcolm, B., & Lastra, D. (2017).
Psilocybin-assisted therapy: A review of a novel treatment for psychiatric disorders.
Journal of Psychoactive Drugs, 49(5), 446-455.
Thomas, K., & Malcolm, B.(2021). Adverse Effects.
Handbook of Medical Hallucinogens,
414.
By Casey Paleos, MD
Alpert, M. D., O’Donnell, K. C., Paleos, C. A., Sola, E., Stauffer, C. S., Wagner, A. C., Nicholas, C. R., & Mithoefer, M. C. (2024).
Psychotherapy in Psychedelic Treatment: Safe, Evidence-Based, and Necessary.
The American journal of psychiatry, 181(1), 76–77. https://doi.org/10.1176/appi.ajp.20230665
O’Donnell, K. C., Anderson, B. T., Barrett, F. S., Bogenschutz, M. P., Grob, C. S., Hendricks, P. S., Kelmendi, B., Nayak, S. M., Nicholas, C. R., Paleos, C. A., Stauffer, C. S., & Gukasyan, N. (2024).
Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues’ Commentary on Psilocybin-Assisted Therapy.
The American journal of psychiatry, 181(1), 74–75. https://doi.org/10.1176/appi.ajp.20230661
Mitchell, J.M., Bogenschutz, M., Lilienstein, A. et al.
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Nat Med 27, 1025–1033 (2021). https://doi.org/10.1038/s41591-021-01336-3
Hull, T. D., Malgaroli, M., Gazzaley, A., Akiki, T. J., Madan, A., Vando, L., … & Paleos, C. (2022).
At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: findings from a large, prospective, open-label effectiveness trial.
Journal of Affective Disorders, 314, 59-67. https://doi.org/10.1016/j.jad.2022.07.004
Paleos, C. A., & Ross, S. (2013).
Ketamine: a light in the darkness.
Multidisciplinary Association for Psychedelic Studies Bulletin, Special Edition, Spring, 28-33.
Mitchell, J.M., Ot’alora G., M., van der Kolk, B. et al.
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.
Nat Med 29, 2473–2480 (2023). https://doi.org/10.1038/s41591-023-02565-4
By Dan Roberts, MD, MSW
Perron, Brian & Glass, Joseph & Ahmedani, Brian & Vaughn, Michael & Roberts, Daniel & Wu, Li-Tzy. (2011).
The prevalence and clinical significance of inhalant withdrawal symptoms among a national sample.
Substance abuse and rehabilitation. 2011. 69-76. 10.2147/SAR.S14937.
VanBronkhorst, Sara & Edwards, Evonne & Roberts, Daniel & Kist, Katie & Evans, Darci & Mahdasian, Alexandra & Blankenship, Kelly. (2017).
4.21 Depression, Suicidality, Substance Use, and Abuse History Among Lesbian, Gay, Bisexual, Transgender, Queer (LGBTQ) Adolescents Who Are Psychiatrically Hospitalized.
Journal of the American Academy of Child & Adolescent Psychiatry. 56. S235. 10.1016/j.jaac.2017.09.237.
Mathai, David & Roberts, Daniel & Nayak, Sandeep & Sepeda, Nathan & Lehrner, Amy & Johnson, Matthew & Lowe, Matthew & Jackson, Heather & Garcia-Romeu, Albert. (2023).
Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use.
10.31234/osf.io/hm6jn.
Vanbronkhorst, Sara B; Roberts, Daniel E; Edwards, Evonne M; Blankenship, Kelly.
Diagnosis and Use of Psychotherapy Among Children and Adolescents Prescribed Antipsychotics.
Journal of psychiatric practice. 2018:24(5):323-330.
Roberts, Daniel; Farahmand, Pantea; Wolkin, Adam.
Nitrous Oxide Inhalant Use Disorder Preceding Symptoms Concerning for Primary Psychotic Illness.
American journal on addictions. 2020:29(6):525-527.
Benville, Julia; Agin-Liebes, Gabrielle; Roberts, Daniel E.; Lo, Sharon; Ghazal, Leila; Franco-Corso, Silvia J.; Ross, Stephen.
Effects of Psilocybin on Suicidal Ideation in Patients With Life-Threatening Cancer.
Biological psychiatry. 2021:89(9):S235-S236.
Roberts, Daniel; Farahmand, Pantea; Wolkin, Adam.
Nitrous Oxide Inhalant Use Disorder Preceding Symptoms Concerning for Primary Psychotic Illness.
American journal on addictions. 2021:30(3):268-268.
Roberts, Daniel; Farahmand, Pantea; Wolkin, Adam.
Psychiatric consequences of nitrous oxide abuse.
Current psychiatry. 2021:20(2):E1-E2.
VanBronkhorst, Sara B; Edwards, Evonne M; Roberts, Daniel E; Kist, Katie; Evans, Darci L; Mohatt, Justin; Blankenship, Kelly.
Suicidality Among Psychiatrically Hospitalized Lesbian, Gay, Bisexual, Transgender, Queer, and/or Questioning Youth: Risk and Protective Factors.
LGBT health. 2021:8(6):395-403.
Kim, Katherine; Roberts, Daniel.
Hallucinogen-related disorders.
Addiction medicine: A case and evidence-based guide by Avery, Jonathan D [Ed]; Hankins, David [Ed]. Cham, Switzerland: Springer Nature Switzerland AG; Switzerland, 2022. ISBN: 978-3-030-86429-3.
Traynor, Jenna M; Roberts, Daniel E; Ross, Stephen; Zeifman, Richard; Choi-Kain, Lois.
MDMA-Assisted Psychotherapy for Borderline Personality Disorder.
Focus : the journal of lifelong learning in psychiatry. 2022:20(4):358-367.
O’Donnell, Kelley C.; Roberts, Daniel E; Ching, Terence H.W.; Glick, Gianni; Goldway, Noam; Gukasyan, Natalie; Hokansen, Jamila; Kelmendi, Benjamin; Ross, Stephen; Yaden, Mary E.; Pittenger, Christopher.
Letter to the Editor: What Is in a Name? The Many Meanings of Psychedelic.
Psychedelic medicine (New Rochelle, N.Y.). 2023.
Zeifman, Richard J; Kettner, Hannes; Pagni, Broc A; Mallard, Austin; Roberts, Daniel E; Erritzoe, David; Ross, Stephen; Carhart-Harris, Robin L.
Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences.
Scientific reports. 2023:13(1).
By Xiaojue Hu, MD
Raison CL, Sanacora G, Woolley J, et al.
Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.
JAMA. 2023;330(9):843–853.
Hu, X. Review of books
Third Culture Kids: Growing Up Among Worlds by D. Pollack & R. E. Van Reken, Raising Global Nomads by R. Pascoe, and The Global Nomad’s Guide to University Transition by T. L. Quick.
Group 2015; Vol. 39 (2): 173-176.
